Swiss Archives of Neurology, Psychiatry and Psychotherapy

91 KB

Open AccessBook Review

Ulfried Geuter: Körperpsychotherapie. Grundriss einer Theorie für die klinische Praxis

by EMH Swiss Medical Publishers Ltd.

Swiss Arch. Neurol. Psychiatry Psychother. 2015, 166(4), 132; https://doi.org/10.4414/sanp.2016.00385 - 1 Jan 2016

Viewed by 34

Abstract

Ulfried Geuter zeigt eindrucksvoll auf, dass eine erlebniszentrierte bzw [...] Full article

353 KB

Open AccessReview

Severe traumatic brain injury in high-income countries

by Chiara S. Haller and Bernhard Walder

Swiss Arch. Neurol. Psychiatry Psychother. 2015, 166(4), 114-119; https://doi.org/10.4414/sanp.2016.00383 - 1 Jan 2016

Cited by 4 | Viewed by 37

Abstract

Severe traumatic brain injury (TBI) is a silent epidemic, and a medical, social truments are used to define severe TBI; all diagnostic instruments have severe TBI populations. In high-income countries the incidence lies between 4 and 000/year, depending on the diagnostic instruments used [...] Read more.

Severe traumatic brain injury (TBI) is a silent epidemic, and a medical, social truments are used to define severe TBI; all diagnostic instruments have severe TBI populations. In high-income countries the incidence lies between 4 and 000/year, depending on the diagnostic instruments used for inclu-using the abbreviated injury scale of the head region (HAIS) >3 as inclusion criteria. In 000/year and in patients >65 mortality lies between 30 and 45% in high-income countries. In Switzerland, the mortal¬ity was 30% (25% in patients ≤65 years, 41% in patients >65 years). The instruments used to estimate functional outcome differ across studies and clinical practice; in research the Glasgow Outcome Coma Scale Extended (GOSE) most often is the instrument of choice. In Switzerland median GOSE scores were 5 (interquartile range [IQR] 3–7) at 3 months and 6 (IQR 4–8) at 6 months post-injury. Health-related quality of life has rarely been investigated; these rare studies reported on improvement over the first year after TBI comparable to functional recovery. Neuropsychological outcome is assessed using test batteries that include cognitive, psychiatric and social aspects of functioning. Prolonged cognitive impairments and psychiatric disturbances, most prevalently affective disorders, were observed after severe TBI. A standardized data collection of patients after TBI may allow interdisciplinary quality improvement initiatives in Switzerland. Full article

97 KB

Open AccessBook Review

Lina Arboleda, Vania Zschokke: Die Borderlinestörung gesprächs- und erzählanalytisch betrachtet

by EMH Swiss Medical Publishers Ltd.

Swiss Arch. Neurol. Psychiatry Psychother. 2015, 166(4), 145-146; https://doi.org/10.4414/sanp.2015.00330 - 1 Jan 2015

Viewed by 30

Abstract

Für psychogene Erkrankungen gilt heute mehr denn je, dass sich ihre Diagnostik und Behandlung zentral auf das stützt, was die Betroffenen im Gespräch mitteilen [...] Full article

161 KB

Open AccessBook Review

Peter Theiss-Abendroth: Ernst Federn Anmerkung zu einem Überlebenden

by Bernhard Küchenhoff

Swiss Arch. Neurol. Psychiatry Psychother. 2015, 166(4), 144-145; https://doi.org/10.4414/sanp.2015.00341 - 1 Jan 2015

Abstract

Am 26.8.2014 wäre Ernst Federn 100 Jahre alt geworden [...] Full article

161 KB

Open AccessBook Review

Stephan Zierz: Muskelerkrankungen

by EMH Swiss Medical Publishers Ltd.

Swiss Arch. Neurol. Psychiatry Psychother. 2015, 166(4), 144; https://doi.org/10.4414/sanp.2015.00332 - 1 Jan 2015

Viewed by 31

Abstract

Das von Felix Jerusalem begründete und nun von Stephan Zierz herausgegebene Buch «Muskelerkrankungen» liegt nach einer Pause von 11 Jahren unter einer vierten, vollständig überarbeiteten Auflage auf [...] Full article

79 KB

Open AccessBook Review

Béla Büki und Alexander A. Tarnutzer: Vertigo and Dizziness

by EMH Swiss Medical Publishers Ltd.

Swiss Arch. Neurol. Psychiatry Psychother. 2015, 166(4), 143-146; https://doi.org/10.4414/sanp.2015.00339 - 1 Jan 2015

Abstract

Den beiden international renommierten Autoren ist es gelungen, in diesem handlichen Buch praxis- und klinikorientiert das Wichtigste und Aktuellste über Schwindel zu präsentieren. Das Buch ist klar aufgebaut und reich illustriert. In zwölf Kapiteln werden alle wichtigen Themen abgehandelt [...] Full article

79 KB

Open AccessBook Review

Fernanda Pedrina, Susanne Hauser: Babys und Kleinkinder

by EMH Swiss Medical Publishers Ltd.

Swiss Arch. Neurol. Psychiatry Psychother. 2015, 166(4), 143-146; https://doi.org/10.4414/sanp.2015.00327 - 1 Jan 2015

Abstract

sem Umfeld seine Integrität bewahren konnte, wie er auch sein psychoanalytisches Wissen als distanzierende Hilfe einsetzen konnte [...] Full article

161 KB

Open AccessBook Review

Joachim Küchenhoff: Der Sinn im Nein und die Gabe des Gesprächs

by EMH Swiss Medical Publishers Ltd.

Swiss Arch. Neurol. Psychiatry Psychother. 2015, 166(4), 143-146; https://doi.org/10.4414/sanp.2015.00322 - 1 Jan 2015

Abstract

Herrn A. geht es um die Negativität, und der Patient weist den Analytiker darauf hin, dass es sein ausdrücklicher Wunsch war, «die Struktur zu verlieren […] dahin zu vegetieren […]» (S. 292) [...] Full article

100 KB

Open AccessBook Review

Jean Laplanche: Leben und Tod in der Psychoanalyse

by EMH Swiss Medical Publishers Ltd.

Swiss Arch. Neurol. Psychiatry Psychother. 2015, 166(4), 143-146; https://doi.org/10.4414/sanp.2015.00316 - 1 Jan 2015

Abstract

Das vorliegende Buch ist der zweite Band einer geplanten deutschen Ausgabe des Werkes von Jean Laplanche im Psychosozial Verlag [...] Full article

232 KB

Open AccessReview

«Off-label-Use» in der alters psychiatrischen Demenzbehandlung

by Dan Georgescu

Swiss Arch. Neurol. Psychiatry Psychother. 2015, 166(4), 135-142; https://doi.org/10.4414/sanp.2015.00336 - 1 Jan 2015

Cited by 2 | Viewed by 30

Abstract

“Off-label use” for dementia treatment in geriatric psychiatry: What the attending physician should know. Prescribing medications for purposes besides those officially approved –off-label use – is a common and burdensome challenge for many physicians. They are concerned by the legal aspect of such [...] Read more.

“Off-label use” for dementia treatment in geriatric psychiatry: What the attending physician should know. Prescribing medications for purposes besides those officially approved –off-label use – is a common and burdensome challenge for many physicians. They are concerned by the legal aspect of such treatments, as well as fears of the excessive bureaucracy they may entail. Based on the current legal framework and developments over the last few years, this article seeks to cast light on certain facets of this issue and to answer questions that often preoccupy physicians – in this case those working in the field of geriatric psychiatry. Moreover, the article discusses potential solutions in order to break free from this unsatisfactory context for all parties – particularly for patients and physicians. Full article

268 KB

Open AccessReview

Positronen-Emissions-Tomographie in der Demenzdiagnostik

by Anton Franz Gietl

Swiss Arch. Neurol. Psychiatry Psychother. 2015, 166(4), 126-134; https://doi.org/10.4414/sanp.2015.00335 - 1 Jan 2015

Cited by 2 | Viewed by 37

Abstract

Positron emission tomography (PET) in diagnosing dementia. The use of positron emission tomography (PET) for diagnosing dementia especially relies upon the PET tracer fluorodeoxyglucose (FDG-PET) and various tracers for detecting the presence of beta-amyloid deposits (amyloid-PET). Reduced cerebral glucose metabolism caused by nerve [...] Read more.

Positron emission tomography (PET) in diagnosing dementia. The use of positron emission tomography (PET) for diagnosing dementia especially relies upon the PET tracer fluorodeoxyglucose (FDG-PET) and various tracers for detecting the presence of beta-amyloid deposits (amyloid-PET). Reduced cerebral glucose metabolism caused by nerve damages is assessed using FDG-PET. Different neurodegenerative disorders can be distinguished through the varying damage patterns they exhibit. If the amyloid-PET fails to detect the presence of plaques, the Alzheimer’s diagnosis is highly unlikely. Patients displaying normal cognitive behaviour may, however, frequently exhibit abnormal amyloid-PET results with increasing age. FDG-PET and amyloid-PET are incorporated as relevant biomarkers into the diagnostic criteria for neurodegenerative diseases. These tools thus help to increase diagnostic reliability and to detect early stages. Researchers deem this necessary, as neurodegenerative diseases may remain asymptomatic for decades and the initial appearance of symptoms is already preceded by considerable loss of synapses and neurons. Drug treatment is presently thought to be effective particularly during early stages. Amyloid-PET is well-suited for the early diagnosis of asymptomatic Alzheimer’s pathologies and its results serve as a selection criterion in clinical trials. Full article

410 KB

Open AccessReview

Schizophrénies et troubles délirants tardifs à l’âge avancé

by Montserrat Mendez, Armin von Gunten and Milena Antunes

Swiss Arch. Neurol. Psychiatry Psychother. 2015, 166(4), 113-125; https://doi.org/10.4414/sanp.2015.00334 - 1 Jan 2015

Cited by 3 | Viewed by 45

Abstract

Schizophrenias and delusional disorders amongst the elderly. Persistent schizophrenias and delusional disorders are classified as primary psychiatric pathologies amongst the elderly. It is crucial to distinguish them from secondary psychotic disorders associated with physical illnesses, such as acute confusion and psychotic symptoms caused [...] Read more.

Schizophrenias and delusional disorders amongst the elderly. Persistent schizophrenias and delusional disorders are classified as primary psychiatric pathologies amongst the elderly. It is crucial to distinguish them from secondary psychotic disorders associated with physical illnesses, such as acute confusion and psychotic symptoms caused by dementia or other somatic pathologies. Employing the concept of a primary psychiatric disorder occurring in an elderly patient is not simple, and each term used to define the concept refers back to an array of various criteria in clinical, psychological, biological, neurological, and cognitive fields. What about very late-onset schizophrenia, occurring after the age of 60 years, for instance? Is this a primary psychiatric illness occurring very late or a secondary pathology caused by brain disease, particularly a degenerative one? Studies reveal controversial results and it is still being debated as to whether the disease has neurodevelopmental or neurodegenerative causes. Due to the variable symptoms and psychiatric, somatic, and cognitive comorbidities associated with psychosis in elderly patients, patient healthcare must not be limited to prescribing an antipsychotic. Once it has been determined whether the psychosis is secondary or primary (old-age-related schizophrenia, late-onset or very late-onset schizophrenia, or late-onset delusional disorder), an aetiological or symptomatic treatment must follow, including a psychotherapeutic approach, close surveillance of the drug treatment and its potential side-effects, rehabilitation steps through community-based care, and psychoeducational support for the family and other professionals in charge of the patient. Our article’s aim has been restricted to summarising our understanding regarding late-onset schizophrenias and delusional disorders amongst the elderly. Full article

231 KB

Open AccessReview

Stroke-unit treatment: long-term effects

by Bruno J. Weder

Swiss Arch. Neurol. Psychiatry Psychother. 2015, 166(4), 1-8; https://doi.org/10.4414/sanp.2015.00344 - 1 Jan 2015

Cited by 1 | Viewed by 36

Abstract

Since the 1990s, stroke units have emerged as core elements in effective acute stroke treatment. Consistent adherence to key processes of stroke care, primarily based on efficient organisational structures, has been the cornerstone of success. On the basis of huge datasets of high [...] Read more.

Since the 1990s, stroke units have emerged as core elements in effective acute stroke treatment. Consistent adherence to key processes of stroke care, primarily based on efficient organisational structures, has been the cornerstone of success. On the basis of huge datasets of high quality there is now conclusive evidence of the significant contribution of stroke unit care to diminished mortality and functional dependency in the long term. In the subjective awareness of the affected individuals quality of life has improved considerably. Meanwhile the concept has emerged as a platform for new ideas and research promoting stroke care and early neurorehabilitation. This dynamic process includes exploring specific treatment of comorbidities and the prevention of early recurrence of stroke, as well as the contribution of occupational and speech and language therapy in the acute phase and their interaction with long-term outcome. Current issues include strategies in assessment and treatment of atrial fibrillation, hypertension and diabetes mellitus at hyperacute and acute stage, models of prognostic value in dysphagia used to prevent its inherent risks, and concepts of early language and speech therapy to enhance functional communication. In neurorehabilitation, targeted treatment referred to pathophysiological mechanisms and perception of idiosyncratic in addition to common aspects of functional impairment are major concerns. Full article

Journal Menu

Journal Browser

Swiss Arch. Neurol. Psychiatry Psychother., Volume 166, Issue 4 (01 2015) – 13 articles

Further Information

Guidelines

MDPI Initiatives

Follow MDPI